Skip to main content
. 2022 Jul 16;17:61. doi: 10.1186/s13000-022-01234-3

Table 3.

Clinicopathologic characteristics of patients by PD-1 expression

Clinicopathologic parameters PD-1
Positive Negative P-value
age 0.01
≤ 50 7 (17.5%) 33(82.5%)
>50 12(12.0%) 88(88.0%)
tumor size 0.416
≤ 2.0 cm 11 (13.3%) 72 (86.7%)
> 2.0 cm 8(14.0%) 49(86.0%)
Menopausal status 0.171
postmenopausal 10(10.8%) 83(89.2%)
menstruating 9(19.1%) 38(80.9%)
Histological subtype 0.902
IDC 15(13.4%) 97(86.6%)
ILC 4(14.3%) 24(85.7%)
Histological classification of IDC 0.243
I 2(6.9%) 27 (93.1%)
II 7 (20.0%) 28 (80%)
III 6 (12.5%) 42 (87.5%)
Nodal metastasis < 0.01
Present 16 (25.8%) 46 (74.2%)
Absent 3 (3.8%) 75 (96.2%)
Lymphovascular Invasion < 0.01
Present 16 (37.2%) 27 (62.8%)
Absent 3 (3.1%) 94 (96.9%)
Ki-67 Index 0.019
<14% 9 (27.2%) 24(72.8%)
>14% 10(9.3%) 97(90.7%)
TNM Clinical Stage < 0.01
I ~ II 6 (6.1%) 92 (93.9%)
III ~ IV 13 (31.0%) 29 (69.0%)
ER 0.047
Positive 7(8.5%) 75(91.5%)
Negative 12(25.0%) 46(75.0%)
PR 0.161
Positive 2(6.1%) 31(93.9%)
Negative 17(15.9%) 90(84.1%)
HER-2 0.596
Positive 6(16.2%) 31(83.8%)
Negative 17(16.5%) 86(83.5%)